Copyright West LLC. Minimum 15 minutes delayed.

News Release

<< Back
Aug 6, 2015

OvaScience Expands AUGMENT℠ Fertility Treatment Offering through IVI Group, the Largest IVF Clinic Network in the World

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that the AUGMENTSM fertility treatment will be introduced to patients at IVI Valencia, a clinic within the IVI Group of 38 in vitro fertilization (IVF) clinics spanning nine countries in Europe, North America, South America and Asia. The AUGMENT treatment is not available in the United States.

“We were pleased to hear from experts at other IVF clinics how the AUGMENT treatment has helped improve success rates in women with very poor prognoses, with an impressive number of ongoing pregnancies,” said Antonio Pellicer, M.D., Ph.D., President of the IVI Group. “We look forward to exploring how the AUGMENT treatment can assist us in achieving more pregnancies for the thousands of women and couples who visit our extensive IVF clinic network each year.”

The IVI Group was founded in Spain as the first medical institution specializing entirely in human reproduction and has grown to become a globally preeminent IVF institution. As a pioneer in new fertility techniques and treatments, more than 100,000 babies have been born with the help of the IVI Group, which performs more than 23,000 IVF cycles annually.

“Our partnership with the IVI Group, the largest clinic network in reproductive medicine, is a major step forward in bringing our AUGMENT treatment to as many women as possible,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “Babies have now been born to women using our AUGMENT treatment at all of the IVF clinics that currently offer it. We eagerly await the births of more healthy babies this year.”

The IVI clinic in Valencia will be the first in the IVI Group to participate in the AUGMENT preceptorship program, which is designed to obtain patient experience and training before making it commercially available. The AUGMENT treatment was introduced using this approach in IVF clinics in other regions. The AUGMENT treatment will be studied versus standard IVF per approval of La Comisión Nacional de Reproducción Humana (CNRHA).

About the AUGMENTSM Treatment

The AUGMENT treatment is the first fertility treatment available to patients based on OvaScience’s proprietary egg precursor (EggPCSM) cell technology. The AUGMENT treatment is designed to improve the health of a woman’s existing eggs and enhance the IVF procedure. The AUGMENT treatment uses energy-producing mitochondria from a woman’s own EggPC cells, which are immature egg cells found in the protective lining of the ovaries, to supplement the existing mitochondria in her eggs. This treatment is designed to improve egg health by increasing the eggs’ energy levels for embryo development. Egg health is a key factor in IVF success. The AUGMENT treatment is available in select international IVF clinics, and initial positive clinical experiences of pregnancies with the treatment have been reported. The AUGMENT treatment is not available in the United States. For more information, please visit

About the IVI Group

Each year around 5,000 couples from 80 countries visit IVI clinics with more than 23,000 IVF cycles performed annually. IVI clinics can be found in Spain, Panama, Chile, Brazil, Argentina, Mexico and Portugal. Since 2012, the IVI Group has had an alliance with NOVA clinics in India, which has given rise to NOVA IVI Fertility. For more information about the IVI Group, visit

About OvaScience

OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit and connect with us on Twitter and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the Company’s business and development plans for the AUGMENT treatment and its two fertility treatments in development, including statements relating to the introduction of the AUGMENT treatment to patients of the IVI Group. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.


Source: OvaScience

Theresa McNeely, 617-299-7356
EVP, Chief Communications Officer
Cara Mayfield, 617-714-9638
Director, Corporate Communications